Beckman Coulter Diagnostics has launched its next generation Hemoglobin A1c (HbA1c) assay with improved performance across all of its chemistry systems. The assay has been standardized for use on all platforms of the company’s AU clinical chemistry systems for offline sample preparation use, in addition to online sample preparation use on the company’s UniCel DxC systems. Additionally, Beckman Coulter has partnered with Canterbury Scientific, Ltd., to distribute the extendSURE liquid ready-to-use control for both the AU and UniCel DxC HbA1c assays.
Measurement of hemoglobin A1c is accepted as a method to measure long-term glucose control in patients with diabetes mellitus. Determination of hemoglobin A1c provides the average level of blood glucose over the previous three months and is an important tool for monitoring the efficiency of dietary control and therapy during treatment for diabetes. The HbA1c assay, when used in conjunction with Beckman Coulter’s Synchron/AU Hemolyzing reagent or HbDil, is intended for the quantitative determination of hemoglobin A1c concentration in human whole blood.
“The new assay and the Canterbury Scientific control will allow physicians to maintain diabetic patients under better glycemic control and better manage complications of the disease,” says Kathleen Orland, vice president, Clinical Chemistry/Immunoassay product management, Beckman Coulter Diagnostics. Learn more about HbA1c testing solutions from Beckman Coulter.
Read more
